{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-001580","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.481954+00:00","generated_at":"2026-05-16T11:42:50.128103+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xilio reports 48.2M Series B warrants exercised for $35.8M, cash runway into Q2 2027","bullets":["48.2M Series B warrants exercised by Dec 31, 2025, yielding $35.8M gross proceeds; issued 8.2M shares and 40M prefunded warrants.","As of Jan 2, 2026, 67.5M shares of common stock outstanding.","48.2M Series C warrants outstanding at $0.75 strike; if fully exercised could add $36.2M gross.","Existing cash plus net proceeds from Series B exercise expected to fund operations into Q2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-001580","json":"https://secwatch.observer/filing/0001193125-26-001580.json","markdown":"https://secwatch.observer/filing/0001193125-26-001580.md","text":"https://secwatch.observer/filing/0001193125-26-001580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/0001193125-26-001580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/xlo-20260102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:42:50.128103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}